Key facts
- Yicura BioMed is based in the Hong Kong Science Park, according to the report.
- CEO Xian Jin said Hong Kong needs more patient capital and talent to commercialize research.
- Jin said biotech start-up fundraising in Hong Kong is never an easy game to play.
Yicura BioMed, a biotechnology start-up based in the Hong Kong Science Park, is heading toward an initial public offering in the city as soon as practicable, CEO Xian Jin said in an interview. The report was published on November 18, 2026.
Jin said Hong Kong needs more patient capital, meaning funding willing to wait longer for returns, and more talent capable of commercializing research and development to sustain the city's biotechnology ecosystem. He said biotech start-up fundraising in Hong Kong is never an easy game to play.
The report did not give a date for the listing, a fundraising target, a valuation or the size of any offering.
